SCINTIX therapy, delivered by the RefleXion X1, uses emissions from cancer cells created by injecting the patient with a radiopharmaceutical to deliver a radiation dose that continuously and autonomously targets the cancer itself. (Photo: Business Wire)
July 21, 2023 — RefleXion Medical, a therapeutic oncology company, today announced that researchers from multiple clinical programs will present new scientific evidence in 28 oral, panel, and poster presentations validating the efficacy and feasibility of the RefleXion X1 machine with SCINTIX biology-guided radiotherapy at the 2023 American Association of Physicists in Medicine (AAPM) Annual Meeting in Houston, July 23-26. The company will also hold multi-target SCINTIX technology interactive demonstrations in booth #501.
“As we are on the cusp of treating patients with SCINTIX therapy, we’re extremely gratified to have this significant scientific presence that includes five oral and panel presentations, and a poster designated as a blue-ribbon recipient,” said Sean Shirvani, M.D., chief medical officer of RefleXion. “Several of these presentations detail our successfully completed clinical study that supported our FDA clearance for SCINTIX therapy, while others explore its breakthrough potential in treating multiple moving tumors.”
The following oral and panel presentations highlight some of the new research about the accuracy of multi-target SCINTIX therapy, as well as the high degree of accuracy in achieving the primary endpoint from BIOGUIDE-X, the first-in-human clinical study for SCINTIX therapy. Detailed information on all 28 presentations may be found here.
Oral Presentations and Panels:
- Oral: Assessment of the Accuracy of Multi-Target Biology-guided RadiotherapyDelivery, Murat Surucu, Ph.D.
Sunday, July 23, 2:21 pm, Room 362
- Panel: Biology-Guided Adaptive Radiotherapy, Nataliya Kovalchuk, Ph.D.
Monday, July 24, 4:35 pm, Room 372
- Oral: Patient Specific Quality Assurance Verification of Biology-guided Radiotherapy Plans from the First-in-Human Clinical Trial, Bin Cai, Ph.D
Tuesday, July 25, 10:45 am, Room 372
- Oral: Demonstration of in-Silico Biology-Guided Radiotherapy Delivery Using Data Acquired on the First Installation of O-Ring Gantry PET/CT Radiotherapy System, Manoj Narayanan, Ph.D.
Tuesday, July 25, 10:55 am, Room 372
- Panel: Adaptive RT on the RefleXion Platform, Murat Surucu, Ph.D.
Wednesday, July 26, 9:15 am, Room 362
RefleXion is also hosting an industry lunch symposium during the AAPM annual meeting at 12:30 PM CDT on July 24. Physicists Murat Surucu, Ph.D., Chunhui Han, Ph.D., and Bin Cai, Ph.D., will share their clinical experience with the X1 and how they are preparing for SCINTIX therapy.
Overcoming the hurdles of targeting and motion management, especially for multiple tumors, is the core challenge in external-beam radiotherapy. SCINTIX therapy, delivered by the RefleXion X1, uses emissions from cancer cells created by injecting the patient with a radiopharmaceutical to deliver a radiation dose that continuously and autonomously targets the cancer itself. Moreover, this fundamental capability simultaneously lights up all targeted tumors in the body during treatment. SCINTIX technology handles tumor motion from all types of movement, including expected motion from internal processes such as breathing and digestion or unexpected movement by a patient.
For more information: www.reflexion.com